Profile

Elisabeth A. Tallant, Ph.D.

Elisabeth A. Tallant, Ph.D.

Professor, Surgical Sciences-Hypertension
Comprehensive Cancer Center
Hypertension and Vascular Research Center
Cancer Biology
Physiology & Pharmacology

Contact Information

Academic: 336-716-2108 | Department: 336-716-2108

Email: atallant@wakehealth.edu

Education & Training

  • Ph.D., University of Tennessee-Memphis , 1983
  • B.S., University of Memphis , 1974
  • Fellowship, University of Alabama-Birmingham, 1986

Memberships

  • Am Assn Of Advancement Of Scie
  • Am Assn for Cancer Research
  • Am Soc Biochem Molecular Bio
  • Am Heart Association
  • Am Physiological Society
  • Cons for SE Hypertension Contr
  • Council For High Blood Pressur
Elisabeth A. Tallant, Ph.D.

Elisabeth A. Tallant, Ph.D.

Professor, Surgical Sciences-Hypertension Comprehensive Cancer Center
Hypertension and Vascular Research Center
Cancer Biology
Physiology & Pharmacology

Research Interests

hypertension, vascular diseases

Contact Information

Academic: 336-716-2108 | Department: 336-716-2108

Email: atallant@wakehealth.edu

Recent Publications

Krishnan B, Smith TL, Dubey P, Zapadka ME, Torti FM, Willingham MC, Tallant EA, Gallagher PE. Angiotensin-(1-7) attenuates metastatic prostate cancer and reduces osteoclastogenesis. Prostate. 2013;73(1):71-82.

McCollum LT, Gallagher PE, Tallant EA. Angiotensin-(1-7) attenuates angiotensin II-induced cardiac remodeling associated with upregulation of dual-specificity phosphatase 1. Am J Physiol Heart Circ Physiol. 2012;302(3):H801-H810.

McCollum LT, Gallagher PE, Tallant EA. Angiotensin-(1-7) abrogates mitogen-stimulated proliferation of cardiac fibroblasts. Peptides. 2012;34(2):380-388.

Garcia-Espinosa MA, Lesser GJ, Debinski W, Tallant EA, Gallagher PE. Angiotensin-(1-7), a peptide hormone with therapeutic potential for the treatment of glioblastomas [abstract]. In: Proceedings of the 103rd Annual Meeting of the Amerian Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, Illinois. Philadelphia (PA): AACR. 2012;():Abstr 1938.

Arter AA, Metheny-Barlow L, Gallagher PE, Tallant EA. Angiotensin-(1-7) inhibits proliferative and fibrotic signaling mechanisms in triple negative breast cancer [abstract]. In: Proceedings of the 103rd Annual Meeting of the Amerian Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, Illinois. Philadelphia (PA): AACR. 2012;():Abstr 5224.

Nautiyal M, Katakam PV, Busija DW, Gallagher PE, Tallant EA, Chappell MC, Diz DI. Differences in oxidative stress status and expression of MKP-1 in dorsal medulla of transgenic rats with altered brain renin-angiotensin system. Am J Physiol Regul Integr Comp Physiol. 2012;303(8):R799-806.

Gallagher PE, Maglic D, Krishnan B, Castellino SM, Tallant EA. Angiotensin-(1-7) inhibits the growth of human pediatric rhabdomyosarcoma in a mouse xenograft model [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando (FL). Philadelphia (PA): AACR. 2011;():Abstr 5349.

Gallagher PE, Cook K, Soto-Pantoja D, Menon J, Tallant EA. Angiotensin peptides and lung cancer. Curr Cancer Drug Targets. 2011;11(4):394-404.

Diz DI, Arnold AC, Nautiyal M, Isa K, Shaltout HA, Tallant EA. Angiotensin peptides and central autonomic regulation. Curr Opin Pharmacol. 2011;11(2):131-137.

Carver KA, Smith TL, Gallagher PE, Tallant EA. Angiotensin-(1-7) attenuates angiotensin II-induced fibrosis through a reduction in connective tissue growth factor [abstract]. Hypertension. 2011;58(5):e178.

Tallant EA, Carver KA, Gallagher PE. Angiotensin-(1-7) reduces cardiac hypertrophy and fibrosis in mRen2.Lewis congenic rats [abstract]. Hypertension. 2011;58(5):e110.

Tallant EA, Holmes CH, Gallagher PE. Inhibition of cancer cell growth by muscadine grape seed and grape skin extracts [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, Florida. Philadelphia (PA): AACR. 2011;():Abstr 4220.

Gallagher PE, Tallant EA, Ferrario CM, inventors; Wake Forest University Health Sciences, assignee. Angiotensin-(1-7) and angiotensin-(1-7) agonists for inhibition of cancer cell growth. United States patent US 8,034,781. 2011 Oct 11. 2011;():.

Varagic J, Ahmad S, Brosnihan KB, Groban L, Chappell MC, Tallant EA, Gallagher PE, Ferrario CM. Decreased cardiac Ang-(1-7) is associated with salt-induced cardiac remodeling and dysfunction. Ther Adv Cardiovasc Dis. 2010;4(1):17-25.

Nautiyal M, Tallant EA, Chappell MC, Diz DI. Mitogen-activated protein kinase phosphatase-1 (MKP-1) is low in dorsal medulla of hypertensive (mRen2)27 transgenic rats [abstract]. FASEB J. 2010;24(1 Meeting Abstracts):955.11.

Cook KL, Metheny-Barlow LJ, Tallant EA, Gallagher PE. Angiotensin-(1-7) reduces fibrosis in orthotopic breast tumors. Cancer Res. 2010;70(21):8319-8328.

Carver KA, Smith TL, Gallagher PE, Tallant EA. Angiotensin-(1-7) reduces angiotensin II-induced remodeling of the microcirculation [abstract]. Hypertension. 2010;56(5):e141-e142.

Nautiyal M, Katakam PV, Busija DW, Gallagher PE, Tallant EA, Chappell MC, Diz DI. Oxidative stress and low expression of mitogen-activated protein kinase phosphatase-1 (MKP-1) in dorsal medulla of hypertensive (mRen2)27 transgenic rats [abstract]. Hypertension. 2010;56(5):e156.

Cook KL, Soto PD, Gallagher P, Tallant EA. Angiotensin-(1-7) inhibition of human breast tumors with distinct hormone receptor expression results in a differential regulation of AKT [abstract]. Cancer Res. 2009;69(2 Suppl):240S.

Soto-Pantoja DR, Petty WJ, Gallagher PE, Tallant EA. Angiotensin-(1-7) inhibits triple negative tumor growth through the inhibition of angiogenesis and a reduction in placental growth factor PIGF [abstract]. Cancer Res. 2009;69(2 Suppl):103S.

Soto-Pantoja DR, Menon J, Gallagher PE, Tallant EA. Angiotensin-(1-7) inhibits tumor angiogenesis in human lung cancer xenografts with a reduction in vascular endothelial growth factor. Mol Cancer Ther. 2009;8(6):1676-1683.

Petty WJ, Miller AA, McCoy TP, Gallagher PE, Tallant EA, Torti FM. Phase I and pharmacokinetic study of angiotensin-(1-7), an endogenous antiangiogenic hormone. Clin Cancer Res. 2009;15(23):7398-7404.

Gallagher PE, Tallant EA. Angiotensin-(1-7) reduces MAP kinase activity by upregulation of the dual-specificity phosphatase DUSP1 [abstract]. Hypertension. 2009;54(4):e35.

Tallant EA, McCollum LT, Gallagher PE. Angiotensin-(1-7) reduces Ang II-induced cardiac hypertrophy with an associated increase in the dual-specificity phosphatase 1 (DUSP1) [abstract]. Hypertension. 2009;54(4):e122.

Petty WJ, Miller AA, McCoy TP, Gallagher PE, Tallant EA, Torti FM. Phase I study of angiotensin-(1-7), an endogenous antiangiogenic hormone: clinical, pharmacokinetic, and biomarker findings [abstract]. Mol Cancer Ther. 2009;8(12 Suppl 1):B208.

Lesser GJ, Carver KA, Newton SJ, Tallant EA, Gallagher PE. Angiotensin-(1-7), a small molecule inhibitor of glioblastoma growth [abstract]. J Clin Oncol. 2009;27(15 Suppl):2024.

Diz DI, Garcia-Espinosa MA, Gegick S, Tommasi EN, Ferrario CM, Tallant EA, Chappell MC, Gallagher PE. Injections of angiotensin-converting enzyme 2 inhibitor MLN4760 into nucleus tractus solitarii reduce baroreceptor reflex sensitivity for heart rate control in rats. Exp Physiol. 2008;93(5):694-700.

Menon J, Miller MS, Soto-Pantoja DR, Callahan MF, Tallant EA, Gallagher PE. Angiotensin-(1-7) reduces lung tumor incidence in a novel bitransgenic Ki-ras G12C mouse model of lung tumorigenesis through a reduction in cyclooxygenase-2 [abstract]. In: Proceedings of the 99th Annual Meeting of the American Association for Cancer Research; 2008 Apr 12-16; San Diego, CA. Philadelphia (PA): AACR. 2008;():Abstr 4654.

Soto-Pantoja DR, Menon J, Gallagher PE, Tallant EA. Angiotensin-(1-7) inhibits the growth of human triple negative breast tumors in an orthotopic model [abstract]. In: Proceedings of the 99th Annual Meeting of the American Association for Cancer Research ; 2008 Apr 12-16; San Diego (CA). Philadelphia (PA): AACR. 2008;():Abstr 2416.

Petty WJ, Miller AA, McCoy TP, Gallagher PE, Tallant EA, Torti FM. Bi-directional translational research with angiotensin-(1-7) uncovers placental growth factor as a therapeutic target [abstract]. In: Proceedings of the 99th Annual Meeting of the American Association for Cancer Research ; 2008 Apr 12-16; San Diego (CA). Philadelphia (PA): AACR. 2008;():Abstr 4968.

Tallant EA, Gallagher PE, Ferrario CM, inventors; Wake Forest University Health Sciences, assignee. Angiotensin (1-7) and angiotensin (1-7) agonists for inhibition of cancer cell growth. United States patent US 7,375,073. 2008 May 20. 2008;():.

Gallagher PE, Ferrario CM, Tallant EA. MAP kinase/phosphatase pathway mediates the regulation of ACE2 by angiotensin peptides. Am J Physiol Cell Physiol. 2008;295(5):C1169-1174.

Lesser G, Carver K, Newton S, Tallant EA, Gallagher P. Angiotensin-(1-7) inhibits the growth of human glioblastoma xenografts in nude mice [abstract]. Neuro Oncol. 2008;10(5):792.

Gallagher PE, Ferrario CM, Tallant EA. Regulation of ACE2 in cardiac myocytes and fibroblasts. Am J Physiol Heart Circ Physiol. 2008;295(6):H2373-79.

Gallagher PE, Soto-Pantoja DR, Tallant EA. Angiotensin-(1-7) reduces endothelial cell growth and migration and increases VEGI to inhibit angiogenesis [abstract]. Hypertension. 2008;52(4):e72.

McCollum LT, Gallagher PE, Tallant EA. Angiotensin-(1-7) attenuates cardiac fibrosis and vascular hypertrophy in a model of angiotensin II-dependent hypertension [abstract]. Hypertension. 2008;52(4):e120.

Tallant EA, McCollum LT, Gallagher PE. Angiotensin-(1-7) increases DUSP-1 and reduces the endothelin-1-mediated increase in COX-2 and PGES-1 in cardiac fibroblasts [abstract]. Hypertension. 2008;52(4):e47-e48.

Trask AJ, Jessup JA, Tallant EA, Chappell MC, Ferrario CM. Renin-independent processing of angiotensin-(1-12) in the rat heart and isolated myocytes [abstract]. Hypertension. 2008;52(4):e45-e46.

Petty WJ, Miller AA, McCoy TP, Gallagher PE, Tallant EA, Torti FM. Phase I trial of angiotensin-(1-7): an endogenous anti-angiogenic hormone [abstract]. J Clin Oncol. 2008;26(15 Suppl):634s.

Menon J, Soto-Pantoja DR, Callahan MF, Cline JM, Ferrario CM, Tallant EA, Gallagher PE. Angiotensin-(1-7) inhibits growth of human lung adenocarcinoma xenografts in nude mice through a reduction in cyclooxygenase-2. Cancer Res. 2007;67(6):2809-2815.

Gallagher PE, Soto-Pantoja DR, Tallant EA. Angiotensin-(1-7) inhibits angiogenesis by reducing endothelial cell growth [abstract]. Hypertension. 2007;50(4):e91.

Tallant EA, Gallagher PE. Angiotensin-(1-7) upregulates the mitogen-activated phosphatase DUSP1 in vascular smooth muscle cells [abstract]. Hypertension. 2007;50(4):e77.

Ferrario CM, Averill DB, Brosnihan KB, Chappell MC, Diz DI, Gallagher PE, Neves L, Tallant EA. Regulation of cardiovascular control mechanisms by angiotensin (1-7) and angiotensin-converting enzyme 2 In: Carey RM, ed. Hypertension and hormone mechanisms. Totowa (NJ): Humana Press;2007: 43-59.

Jessup JA, Gallagher PE, Averill DB, Brosnihan KB, Tallant EA, Chappell MC, Ferrario CM. Effect of angiotensin II blockade on a new congenic model of hypertension derived from transgenic Ren-2 rats. Am J Physiol Heart Circ Physiol. 2006;291(5):H2166-2172.

Whaley-Connell AT, Chowdhury NA, Hayden MR, Stump CS, Habibi J, Wiedmeyer CE, Gallagher PE, Tallant EA, Cooper SA, Ferrario C, et al. Oxidative stress and glomerular filtration barrier injury: role of the renin-angiotensin system in the Ren2 transgenic rat. Am J Physiol Renal Physiol. 2006;291(6):F1308-1314.

Diz DI, Tommasi EN, Ferrario CM, Tallant EA, Gallagher PE. ACE2 inhibition in the nucleus of the solitary tract reduces baroreceptor reflex sensitivity [abstract]. Hypertension. 2006;48(4):e87.

Gallagher PE, Ferrario CM, Tallant EA. Molecular mechanisms for the regulation of angiotensin converting enzyme 2 by angiotensin peptides in vascular smooth muscle cells [abstract]. Hypertension. 2006;48(4):e72.

McCollum LT, Gallagher PE, Ferrario CM, Tallant EA. Angiotensin-(1-7) reduces COX-2 in cardiac fibroblasts [abstract]. Hypertension. 2006;48(4):e79.

Tallant EA, Ferrario CM, Gallagher PE. Cardioprotective role for angiotensin-(1-7) and angiotensin converting enzyme 2 in the heart. Future Cardiol. 2006;2(3):335-342.

Gallagher PE, Tallant EA, Ferrario CM. Angiotensin converting enzyme 2: a potential target for cardiovascular therapy In: Re RN, DiPette DJ, Schiffrin EL, Sowers JR, eds. Molecular mechanisms in hypertension. New York: Taylor & Francis;2006: 51-59.

Tallant EA, Menon J, Soto-Pantoja DR, Gallagher PE. Angiotensin peptides and cancer In: Kastin AJ, ed. Handbook of biologically active peptides. Boston: Academic Press;2006: 459-465.

Menon J, Tallant EA, Gallagher PE. Experimental and molecular therapeutics 17: novel therapeutic targets [abstract]. In: Proceedings of the 97th Annual Meeting of the American Association for Cancer Research ; 2006 Apr 1-5; Washington, DC. Philadelphia (PA): AACR. 2006;():Abstr 2160.

Soto-Pantoja DR, Gallagher PE, Tallant EA. Inhibition of angiogenesis by angiotensin-(1-7) [abstract]. In: Proceedings of the 97th Annual Meeting of the American Association for Cancer Research ; 2006 Apr 1-5; Washington, DC. Philadelphia (PA): AACR. 2006;():Abstr 950.

All Publications

For a listing of recent publications, refer to PubMed, a service provided by the National Library of Medicine.

For a list of earlier publications, visit the Carpenter Library Publication Search.

Professor, Surgical Sciences-Hypertension

Quick Reference

Request an Appointment
New Patients

336-716-WAKE
888-716-WAKE

Existing patients may contact the clinic directly.
Find a Doctor Ways to Give
USNWR 2012-2013Best Doctors 2011-2012 AwardMagnet Hospital RecognitionIndependent Measures of Excellence298 Wake Forest Baptist Physicians Named to Prestigious 2013 Best Doctors

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.